Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Liping Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4810-1495; OpenAlex author ID A5091539744. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 5 papers · 2020: 4 papers · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper

Papers 26

  1. Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe. Last author DOI 10.1038/s41419-025-07835-2↗
  2. Fisetin disrupts mitochondrial homeostasis via superoxide dismutase 2 acetylation in pancreatic adenocarcinoma. Last author DOI 10.1002/ptr.8296↗
  3. Diagnostic plasma small extracellular vesicles miRNA signatures for pancreatic cancer using machine learning methods. Co-author DOI 10.1016/j.tranon.2023.101847↗
  4. Discovery of an 8-oxoguanine regulator PCBP1 inhibitor by virtual screening and its synergistic effects with ROS-modulating agents in pancreatic cancer. Last author DOI 10.3389/fmolb.2024.1441550↗
  5. Sirtuin4 impacts mitochondrial homeostasis in pancreatic cancer cells by reducing the stability of AlkB homolog 1 via deacetylation of the HRD1-SEL1L complex. Last author DOI 10.1016/j.bbagrm.2023.194941↗
  6. Post-translational modification of CDK1-STAT3 signaling by fisetin suppresses pancreatic cancer stem cell properties. Co-author DOI 10.1186/s13578-023-01118-z↗
  7. Scaffold-based three-dimensional cell model of pancreatic cancer is more suitable than scaffold-free three-dimensional cell model of pancreatic cancer for drug… Last author DOI 10.1007/s10616-022-00553-z↗
  8. ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.01.013↗
  9. VRK2 activates TNFα/NF-κB signaling by phosphorylating IKKβ in pancreatic cancer. Last author DOI 10.7150/ijbs.66313↗
  10. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Last author DOI 10.1038/s41419-020-03019-2↗
  11. Pancreatic cancer-derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK-mediated endoplasmic reticulum stress. Last author DOI 10.1096/fj.201902186r↗
  12. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000308↗
  13. Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanopartic… Last author DOI 10.3892/ol.2020.11302↗
  14. The distinct role of CD73 in the progression of pancreatic cancer. Last author DOI 10.1007/s00109-018-01742-0↗
  15. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Last author DOI 10.1038/s41419-019-1366-y↗
  16. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. Last author DOI 10.1186/s12885-019-6145-8↗
  17. Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis. Co-author DOI 10.7150/jca.27405↗
  18. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.31191↗
  19. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway. Last author DOI 10.1089/jir.2018.0070↗
  20. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. Last author DOI 10.7150/jca.21046↗
  21. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.21683↗
  22. Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. Last author DOI 10.7150/jca.21749↗
  23. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer. Last author DOI 10.1038/s41598-017-08479-9↗
  24. A novel scoring system to analyze combined effect of lifestyle factors on pancreatic cancer risk: a retrospective case-control study. Last author DOI 10.1038/s41598-017-13182-w↗
  25. Increasing the immune activity of exosomes: the effect of miRNA-depleted exosome proteins on activating dendritic cell/cytokine-induced killer cells against pa… Last author DOI 10.1631/jzus.b1500305↗
  26. Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.3892/or.2013.2246↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guoping Ding · 17 shared papers, 2016–2023 · strength 1.86
  2. Shengnan Jia · 13 shared papers, 2017–2023 · strength 1.54
  3. Chaolei Zhang · 6 shared papers, 2022–2025 · strength 1.21
  4. Liangjing Zhou · 8 shared papers, 2017–2024 · strength 0.91
  5. Shengnan Jia · 4 shared papers, 2023–2024 · strength 0.86
  6. Xiaodong Xu · 6 shared papers, 2018–2023 · strength 0.72
  7. Xiaofan Pu · 4 shared papers, 2020–2024 · strength 0.66
  8. Tao Shen · 5 shared papers, 2017–2024 · strength 0.63
  9. Dongnan Ping · 3 shared papers, 2020–2023 · strength 0.51
  10. Mingjie Zhang · 5 shared papers, 2018–2020 · strength 0.51
  11. Tianshu Pang · 3 shared papers, 2017–2024 · strength 0.45
  12. Dafei Xie · 2 shared papers, 2022–2024 · strength 0.44
  13. Chaojie Huang · 2 shared papers, 2022–2025 · strength 0.42
  14. Yimin Ding · 2 shared papers, 2023–2024 · strength 0.42
  15. Zhengrong Wu · 4 shared papers, 2016–2020 · strength 0.40
  16. Kexiong Qiao · 2 shared papers, 2022–2024 · strength 0.39
  17. Jionghuang Chen · 3 shared papers, 2018–2022 · strength 0.35
  18. Zhengrong Wu · 3 shared papers, 2017–2019 · strength 0.31
  19. Jingyun Chen · 1 shared paper, 2025 · strength 0.27
  20. Guixing Jiang · 3 shared papers, 2017–2018 · strength 0.26
  21. Weihua Yu · 2 shared papers, 2019 · strength 0.20
  22. Ting Zhao · 2 shared papers, 2018–2019 · strength 0.20
  23. Dan Li · 1 shared paper, 2020 · strength 0.12
  24. Xu Dong Sun · 1 shared paper, 2020 · strength 0.10
  25. Qiang Yan · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.